FULMINANT HEPATIC-FAILURE ASSOCIATED WITH ETODOLAC USE

Authors
MABEE CL MABEE SW BAKER PB KIRKPATRICK RB LEVINE EJ
Citation
Cl. Mabee et al., FULMINANT HEPATIC-FAILURE ASSOCIATED WITH ETODOLAC USE, The American journal of gastroenterology, 90(4), 1995, pp. 659-661
Citations number
10
Categorie Soggetti
Gastroenterology & Hepatology
Journal title
The American journal of gastroenterology → ACNP
ISSN journal
00029270
Volume
90
Issue
4
Year of publication
1995
Pages
659 - 661
Database
ISI
SICI code
0002-9270(1995)90:4<659:FHAWEU>2.0.ZU;2-R
Abstract
Etodolac is a new pyranocarboxylic acid nonsteroidal antiinflammatory agent with a unique chemical structure indicated for use in patients w ith painful musculoskeletal disorders and rheumatoid disease. Hepatoto xicity, in the form of reversible elevations in transaminases or bilir ubin, occurs rarely. We present the first reported case of fulminant h epatic failure related to etodolac.